The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a company spokesperson told Reuters, contrary to social media posts sharing an ...
NEW YORK (Reuters) — The chief executive of Germany’s BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States ...
BioNTech said Thursday it has agreed to acquire smaller biotech CureVac in a $1.25 billion all-stock deal in a push to advance its cancer drug portfolio. CureVac stock soared 31% to $5.33 in premarket ...
BioNTech hopes its purchase of CureVac will help boost its research into cancer treatments - Copyright AFP Sam PANTHAKY BioNTech hopes its purchase of CureVac will ...
BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...
The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results